A new two-dose vaccine developed by French and British manufacturers is 100 per cent effective against severe disease and hospitalisation from Covid-19, the companies have said.
French drugmaker Sanofi and its British partner GlaxoSmithKline fell behind in the race to develop a vaccine, but new data suggest the jab will have a vital role to play in the long-term fight against Covid.
